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The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), a novel virus, was emerged in Wuhan, China,
in December 2019. On March 11th, the World Health Orga-
nization (WHO) declared the outbreak of coronavirus
disease 2019, and termed ‘‘COVID-19,’’ a pandemic. At that
point, there were 118,000 confirmed cases and 4,291 victims
worldwide (1). Since then, researchers around the world
have been analyzing the genetic structure, multiplication
patterns and the cellular mechanisms of SARS-CoV-2 in vitro
and in vivo to identify possible drug targets (2).
Four months after the onset of the outbreak, physicians
from different countries and laboratories have proposed
several empirical treatments for COVID-19. To date, there are
over 335 COVID-19–related clinical trials registered on the
National Institutes of Health (NIH) website (3). The propo-
sed drugs aim to prevent viral entry into host cells, interrupt
viral replication, and attenuate virus-induced inflammatory
responses. Examples of the drugs being tested for each of
these mechanisms are recombinant human angiotensin con-
verting enzyme 2 (RhACE2), the antiviral remdesivir, and the
immunosuppressant, tocilizumab, respectively.
However, the most promising drugs appear to be old
drugs, the antimalarial and immunomodulatory medication,
chloroquine and its hydroxy analog, hydroxychloroquine.
Chloroquine and hydroxychloroquine are by far the most
popular drugs proposed for treatment and prophylaxis,
appearing in 97 of the COVID-19 clinical trials registered on
the NIH site. These aminoquinolines, which were discovered
in 1934 and are inexpensively produced in several countries,
and have well-known pharmacokinetic and pharmacody-
namic properties. The antiviral mechanisms of chloroquine
are based on its capacity to increase the endosomal pH.
This prevents enveloped viruses, such as those belonging to
the Coronaviridae family (e.g., SARS-CoV-2), from entering
and releasing their genetic material into the host cells and
from replicating their envelopes. Furthermore, in severe
and complicated COVID-19 cases, the anti-inflammatory
effects of chloroquine/hydroxychloroquine may also be of
importance, as both medications can suppress the produc-
tion and release of tumor necrosis factor (TNF) and inter-
leukin 6 (IL-6) (4).
While the mechanisms of action of chloroquine/hydroxy-
chloroquine are well-established, so are the side effects.
Serious retinopathies and cardiopathies associated with
bioaccumulation of the drugs are described in literature (5).
One study at the Clinics Hospital of the University of São
Paulo evaluated 350 patients with systemic lupus erythema-
tosus who were treated with chloroquine. The prevalence of
side effects was 35.7%, with the most common being ocular
alterations (17%), followed by gastrointestinal symptoms
(10%), and dermatological (3.4%), neuromuscular (1.7%), and
psychiatric alterations (0.3%) (6). In Brazil, a phase 2 clinical
trial on COVID-19 sponsored by the state of Amazonas was
suspended after 25% of patients developed QT prolongation
(4500 m/s) owing to cardiotoxicity (7).
Although chloroquine/hydroxychloroquine might yield
promising results, they should not be announced as a cure by
politicians and the mass media, as they have never been
tested as treatments for Coronaviridae viruses. Clinical trials
are ongoing during the course of this pandemic, yet no
scientific evidence has been found to support the widespread
use of these medications. Table 1 lists a few trials in
advanced phases that have randomized allocation, double
masking, and significant numbers of proposed participants.
However, none of them have reported results as of yet.
Recent declarations by the President of Brazil recommend-
ing the indiscriminate use of chloroquine resulted in a shortage
of the drug in several cities (8). Aside from the lack of evidence
supporting his proclamations, the president’s action hampered
the treatment of patients who truly need chloroquine for
systemic lupus erythematosus and rheumatoid arthritis.
Pronouncements by the French president also appeared to
have pressurized French doctors to prescribe the drug, despite
its unconfirmed efficacy and many possible side effects (9).
The same situation occurred in the United States (USA); the
country’s president has endorsed chloroquine in a highly poli-
ticized debate over its use (10).
A serious health system should not encourage protocols
based on political beliefs or case reports. Scientific trial
phases exist and are in constant review so we can guarantee
some basic level of safety regarding prescription medications.DOI: 10.6061/clinics/2020/e1928
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Ignoring or skipping these phases can result in manmade
medical disasters, such as the thalidomide-induced teratogen-
esis tragedies in the 20th century, which resulted in more than
10,000 children were born with debilitating malformations,
leading to the scientific community being forced to rethink
interventional studies and the approval process for new drugs
(11). Drug repositioning is possible and encouraged in case
of pandemics, but chloroquine/hydroxychloroquine should
not be recommended to the general population as if these
medications were supported by grade 1a evidence (12).
Affirmations of the drugs’ effectiveness, such as those by
some of our world leaders in the middle of the pandemic will
only spread fear and the erroneous belief in chloroquine/
hydroxychloroquine as a panacea.
In summary, there are still no effective treatments for
COVID-19. Though chloroquine/hydroxychloroquine may be
promising, their use should be restricted to ongoing clinical
trials until we have enough evidence to recommend it to the
general population. We must consider the long-term con-
sequences of chloroquine/hydroxychloroquine administra-
tion and respect the scientific approach. A well-established,
evidence-based health care policy may save more lives than a
swift implementation of unsupported recommendations.
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Table 1 - Ongoing randomized, double-blind clinical trials on the therapeutic and prophylactic use of chloroquine/hydroxychloroquine
in COVID-19 patients.


























9 NCT04342221 Germany Hydroxychloroquine Phase 3 220
NCT04329923 United States Hydroxychloroquine Phase 2 400
NCT04340544 Germany Hydroxychloroquine Phase 3 2700
NCT04333654 United States Hydroxychloroquine and SAR321068 Phase 1 210
NCT04315896 Mexico Hydroxychloroquine Phase 3 500
NCT04308668 United States Hydroxychloroquine Phase 3 3000
NCT04329611 Canada Hydroxychloroquine Phase 3 1660
NCT04332991 United States Hydroxychloroquine Phase 3 510
NCT04325893 France Hydroxychloroquine Phase 3 1300



























9 NCT04334928 Spain Emtricitabine/Tenofovir Disoproxil,
Hydroxychloroquine and Placebo
Phase 3 4000
NCT04341441 United States Hydroxychloroquine Phase 3 3000
NCT04336748 Austria Hydroxychloroquine Phase 3 440
NCT04334148 United States Hydroxychloroquine and Placebo Phase 3 15000
NCT04328467 United States Hydroxychloroquine Phase 3 3500
NCT04328285 France Hydroxychloroquine, Lopinavir/Ritonavir
and Placebo
Phase 3 1200
NCT04303507 United States Chloroquine/Hydroxychloroquine Not applicable 40000
Legend: COVID-19 = coronavirus disease 2019; NTC= National Clinical Trial.
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